Considering the claims, page-70

Yes if it was superior SO tpm would start to eat the tpgs market across a range of injectables , pharmaceuticals, cosmetics , feeds etc . All poh need to do is to conduct a range of comparison studies and if successful publish the findings . But that appears been avoided like the plague . Strange eh ? A bit like not presenting their pain science to industry conference's . You can almost smell Mylans defense and assault during the recent arbitration cant you ? Its unfortunate we will never be able to hear the arbitrators opinion prior to the award .